메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background/Aims: The dose of mycophenolate mofetil (MMF) has been reduced in Asia due to side effects associatedwith the conventional fixed dose of 2-3 g/day. We aimed to determine the pharmacokinetics of a reduced dose of MMFand to validate its feasibility in combination with tacrolimus in living-donor liver transplantation (LDLT). Methods: Two sequential studies were performed in adult LDLT between October 2009 and 2011. First, we performed aprospective pharmacokinetic study in 15 recipients. We measured the area under the curve from 0 to 12 hours (AUC0–12)for mycophenolic acid at postoperative days 7 and 14, and we performed a protocol biopsy before discharge. Second,among 215 recipients, we reviewed 74 patients who were initially administered a reduced dose of MMF (1.0 g/day) withtacrolimus (trough, 8-12 ng/mL during the first month, and 5-8 ng/mL thereafter), with a 1-year follow-up. We performedprotocol biopsies at 2 weeks and 1 year post-LDLT. Results: In the first part of study, AUC0–12 was less than 30 mgh/L in 93.3% of cases. In the second, validating study, 41.9%of the recipients needed dose reduction or cessation due to side effects within the first year after LDLT. At 12 monthspost-LDLT, 17.6% of the recipients were administered a lower dose of MMF (0.5 g/day), and 16.2% needed permanentcessation due to side effects. The 1- and 12-month rejection-free survival rates were 98.6% and 97.3%, respectively. Conclusions: A reduced dose of MMF was associated with low blood levels compared to the existing recommendedtherapeutic range. However, reducing the dose of MMF combined with a low level of tacrolimus was feasible clinically,with an excellent short-term outcome in LDLT.

목차

등록된 정보가 없습니다.

참고문헌 (22)

참고문헌 신청

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0